Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients

Seung Jin Han, Kyu Yeon Hur, Yu Seun Kim, Eun Seok Kang, Soon Il Kim, Myoung Soo Kim, Jung Young Kwak, Dae Jung Kim, Sung Hee Choi, Bong Soo Cha, Hyun Chul Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes.Methods. Eighty-three patients without diabetes were randomly assigned to either the pioglitazone group or the control group. Carotid intima-media thickness (IMT), serum adiponectin level and lipid profile were assessed before transplantation and at 12 months after transplantation. Insulin secretory function and insulin resistance were evaluated by the oral glucose tolerance test.Results. The pioglitazone group showed a significant reduction in the mean and maximum carotid IMT compared with the control group after 12 months (mean carotid IMT, 0.05 ± 0.04 vs-0.03 ± 0.07mm, P < 0.001; maximum carotid IMT, 0.08 ± 0.05 vs-0.05 ± 0.09mm, P < 0.001). Pioglitazone increased the adiponectin level, and the change in adiponectin was negatively correlated with carotid IMT changes. Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 ± 3.1×10-2 vs +1.1 ± 3.7×10 -2, P = 0.036).Conclusions. These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes.

Original languageEnglish
Pages (from-to)976-984
Number of pages9
JournalNephrology Dialysis Transplantation
Volume25
Issue number3
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

pioglitazone
Carotid Intima-Media Thickness
Allografts
Insulin Resistance
Atherosclerosis
Kidney
Adiponectin
Control Groups
Transplantation
Glucose Tolerance Test
Therapeutics
Insulin

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Cite this

Han, Seung Jin ; Hur, Kyu Yeon ; Kim, Yu Seun ; Kang, Eun Seok ; Kim, Soon Il ; Kim, Myoung Soo ; Kwak, Jung Young ; Kim, Dae Jung ; Choi, Sung Hee ; Cha, Bong Soo ; Lee, Hyun Chul. / Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. In: Nephrology Dialysis Transplantation. 2010 ; Vol. 25, No. 3. pp. 976-984.
@article{c8b7200d567b4eecb3cb0608493dddd3,
title = "Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients",
abstract = "Background. The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes.Methods. Eighty-three patients without diabetes were randomly assigned to either the pioglitazone group or the control group. Carotid intima-media thickness (IMT), serum adiponectin level and lipid profile were assessed before transplantation and at 12 months after transplantation. Insulin secretory function and insulin resistance were evaluated by the oral glucose tolerance test.Results. The pioglitazone group showed a significant reduction in the mean and maximum carotid IMT compared with the control group after 12 months (mean carotid IMT, 0.05 ± 0.04 vs-0.03 ± 0.07mm, P < 0.001; maximum carotid IMT, 0.08 ± 0.05 vs-0.05 ± 0.09mm, P < 0.001). Pioglitazone increased the adiponectin level, and the change in adiponectin was negatively correlated with carotid IMT changes. Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 ± 3.1×10-2 vs +1.1 ± 3.7×10 -2, P = 0.036).Conclusions. These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes.",
author = "Han, {Seung Jin} and Hur, {Kyu Yeon} and Kim, {Yu Seun} and Kang, {Eun Seok} and Kim, {Soon Il} and Kim, {Myoung Soo} and Kwak, {Jung Young} and Kim, {Dae Jung} and Choi, {Sung Hee} and Cha, {Bong Soo} and Lee, {Hyun Chul}",
year = "2010",
month = "3",
day = "1",
doi = "10.1093/ndt/gfp567",
language = "English",
volume = "25",
pages = "976--984",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "3",

}

Han, SJ, Hur, KY, Kim, YS, Kang, ES, Kim, SI, Kim, MS, Kwak, JY, Kim, DJ, Choi, SH, Cha, BS & Lee, HC 2010, 'Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients', Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 976-984. https://doi.org/10.1093/ndt/gfp567

Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. / Han, Seung Jin; Hur, Kyu Yeon; Kim, Yu Seun; Kang, Eun Seok; Kim, Soon Il; Kim, Myoung Soo; Kwak, Jung Young; Kim, Dae Jung; Choi, Sung Hee; Cha, Bong Soo; Lee, Hyun Chul.

In: Nephrology Dialysis Transplantation, Vol. 25, No. 3, 01.03.2010, p. 976-984.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients

AU - Han, Seung Jin

AU - Hur, Kyu Yeon

AU - Kim, Yu Seun

AU - Kang, Eun Seok

AU - Kim, Soon Il

AU - Kim, Myoung Soo

AU - Kwak, Jung Young

AU - Kim, Dae Jung

AU - Choi, Sung Hee

AU - Cha, Bong Soo

AU - Lee, Hyun Chul

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Background. The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes.Methods. Eighty-three patients without diabetes were randomly assigned to either the pioglitazone group or the control group. Carotid intima-media thickness (IMT), serum adiponectin level and lipid profile were assessed before transplantation and at 12 months after transplantation. Insulin secretory function and insulin resistance were evaluated by the oral glucose tolerance test.Results. The pioglitazone group showed a significant reduction in the mean and maximum carotid IMT compared with the control group after 12 months (mean carotid IMT, 0.05 ± 0.04 vs-0.03 ± 0.07mm, P < 0.001; maximum carotid IMT, 0.08 ± 0.05 vs-0.05 ± 0.09mm, P < 0.001). Pioglitazone increased the adiponectin level, and the change in adiponectin was negatively correlated with carotid IMT changes. Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 ± 3.1×10-2 vs +1.1 ± 3.7×10 -2, P = 0.036).Conclusions. These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes.

AB - Background. The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes.Methods. Eighty-three patients without diabetes were randomly assigned to either the pioglitazone group or the control group. Carotid intima-media thickness (IMT), serum adiponectin level and lipid profile were assessed before transplantation and at 12 months after transplantation. Insulin secretory function and insulin resistance were evaluated by the oral glucose tolerance test.Results. The pioglitazone group showed a significant reduction in the mean and maximum carotid IMT compared with the control group after 12 months (mean carotid IMT, 0.05 ± 0.04 vs-0.03 ± 0.07mm, P < 0.001; maximum carotid IMT, 0.08 ± 0.05 vs-0.05 ± 0.09mm, P < 0.001). Pioglitazone increased the adiponectin level, and the change in adiponectin was negatively correlated with carotid IMT changes. Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 ± 3.1×10-2 vs +1.1 ± 3.7×10 -2, P = 0.036).Conclusions. These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes.

UR - http://www.scopus.com/inward/record.url?scp=77649209056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649209056&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfp567

DO - 10.1093/ndt/gfp567

M3 - Article

C2 - 19875376

AN - SCOPUS:77649209056

VL - 25

SP - 976

EP - 984

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 3

ER -